BTIG analyst Kambiz Yazdi raised the firm’s price target on Sionna Therapeutics (SION) to $58 from $50 and keeps a Buy rating on the shares. A central element of the firm’s thesis is the strong preclinical Cystic Fibrosis Human Bronchial Epithelial assay data, where its NBD1 candidates showed high activity, the analyst tells investors in a research note The assay, long used by Vertex (VRTX) and predictive of clinical outcomes, has been calibrated by Sionna to Vertex’s industry gold standard, supporting confidence in its translational potential, the firm says.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SION:
- Coty downgraded, Spruce Biosciences initiated: Wall Street’s top analyst calls
- Sionna Therapeutics initiated with an Outperform at LifeSci Capital
- Sionna Therapeutics: NBD1-Targeted CFTR Stabilization Strategy Positions Pipeline for Best-in-Class Efficacy and Blockbuster Upside in Cystic Fibrosis
- Midday Fly By: Nvidia invests in Synopsys, U.S. strikes pharma deal with UK
- Sionna downgraded to Underperform from Sector Perform at RBC Capital